Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

October 30, 2026

Consolidated Financial Results for the Six Months Ended September 30, 2026 (Under Japanese GAAP)

Company name: Japan Lifeline Co., Ltd.
Listing: Tokyo Stock Exchange
Securities code: 7575
URL: https://www.japanlifeline.com/
Representative: Keisuke Suzuki, President and Chief Executive Officer
Inquiries: Takeyoshi Egawa, Director, and Chief Financial Officer
Telephone: +81-3-6711-5200
Scheduled date to file semi-annual securities report: November 13, 2026
Scheduled date to commence dividend payments: December 15, 2026
Preparation of supplementary material on financial results: Yes
Holding of financial results briefing: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the six months ended September 30, 2026 (April 1, 2026–September 30, 2026)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Net income attributable to owners of the parent	
Six months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
September 30, 2026	31,353	7.1	5,468	(17.4)	6,040	(8.8)	4,430	(7.2)
September 30, 2025	29,285	4.6	6,620	5.7	6,624	7.4	4,774	7.7

Note: Comprehensive income Six months ended September 30, 2026: ¥4,254 million [(8.8)%]
Six months ended September 30, 2025: ¥4,667 million [(0.3)%]

	Basic earnings per share	Diluted earnings per share
Six months ended	Yen	Yen
September 30, 2026	63.15	–
September 30, 2025	68.08	68.08

(2) Consolidated financial position

	Total assets	Total net assets	Equity ratio
As of	Millions of yen	Millions of yen	%
September 30, 2026	80,005	66,414	82.9
March 31, 2026	80,211	65,897	82.1

Reference: Equity (Shareholders' equity + Accumulated other comprehensive income)
As of September 30, 2026: ¥66,332 million
As of March 31, 2026: ¥65,850 million

2. Dividends

	Annual dividends per share				
	Q1-end	Q2-end	Q3-end	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	–	0.00	–	54.00	54.00
Fiscal year ending March 31, 2027	–	25.00			
Fiscal year ending March 31, 2027 (forecast)			–	56.00	81.00

Notes: 1. Revisions to the most recently announced dividends forecast: None
2. Breakdown of Q2-end dividend for the fiscal year ending March 31, 2027
Ordinary dividend: ¥0.00; commemorative dividend: ¥25.00
Breakdown of year-end dividend for the fiscal year ending March 31, 2027 (forecast):
Ordinary dividend: ¥56.00; commemorative dividend: ¥0.00

3. Consolidated earnings forecast for the fiscal year ending March 31, 2027 (April 1, 2026–March 31, 2027)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Net income attributable to owners of the parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	63,200	6.8	10,700	(15.1)	10,800	(14.2)	8,000	(14.4)	114.02

Note: Revisions to the most recently announced earnings forecast: None

* Notes

(1) Changes in significant subsidiaries (changes in specified subsidiaries resulting in changes in the scope of consolidation) during the period: Yes
Newly included: 1 (JLL Med USA Inc.)
Excluded: None

(2) Application of accounting treatments specific to the preparation of semi-annual consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement
(i) Changes in accounting policies due to revisions to accounting standards and other pronouncements: None
(ii) Changes in accounting policies due to reasons other than (i): None
(iii) Changes in accounting estimates: None
(iv) Restatement: None

(4) Number of shares issued (common stock)

(i) Total number of shares issued at the end of the period (including treasury stock)

As of September 30, 2026	71,300,000 shares
As of March 31, 2026	71,300,000 shares

(ii) Number of shares of treasury stock at the end of the period

As of September 30, 2026	1,134,058 shares
As of March 31, 2026	1,145,522 shares

(iii) Average number of shares outstanding during the period

Six months ended September 30, 2026	70,160,889 shares
Six months ended September 30, 2025	70,129,451 shares

Note: The Company has adopted a Board Incentive Plan (BIP) trust, and the Company's shares held by the trust are included in the treasury stock deducted in the calculation of the number of shares of treasury stock at the end of the period and the average number of shares outstanding during the period.

* Semi-annual financial results reports are exempt from review conducted by certified public accountants or an audit firm.

* Proper use of earnings forecast, and other special matters
The forward-looking statements including earnings forecasts contained in this document are based on information currently available to the Company and certain assumptions that are deemed to be reasonable. Accordingly, the Company does not guarantee the achievement of the forecast, and actual results may differ significantly from the forecast due to various factors. For the assumptions for earnings forecasts and cautions concerning the use thereof, please refer to "1. Overview of Financial Performance, (3) Consolidated financial guidance" on page 7 of the attached materials.

Contents of Attached Materials

1. Overview of Financial Performance 2
(1) Operating results 2
(2) Financial position 6
(3) Consolidated financial guidance 7
2. Interim Consolidated Financial Statements and Major Notes 8
(1) Interim consolidated balance sheets 8
(2) Interim consolidated statements of income and interim consolidated statements of comprehensive income 9
(3) Interim consolidated statements of cash flows 10
(4) Notes to interim consolidated financial statements 11
Going concern assumption 11
Significant changes in shareholders' equity 11
Changes in scope of consolidation or application of equity method 11
Interim consolidated statements of cash flows 11
Segment information, etc. 11
Significant subsequent events 11
3. Other 12
Status of production, orders received and sales 12

1. Overview of Financial Performance

(1) Operating results

Forward-looking statements below are based on our judgment as of September 30, 2026.

Business environment

Japan Lifeline is engaged mainly in the manufacture and sale of highly controlled medical devices, primarily focusing on cardiac devices, for general hospitals in Japan.

The business environment surrounding Japan's medical devices industry is characterized by the three main dynamics of 1) expanding structural demand driven by increase in the elderly population, 2) strained medical care delivery system, and 3) changes in the macroeconomy such as weak yen and inflation, and they are having an increasingly significant impact on the performance of individual companies. In this environment, medical trends in the market have been constantly changing and the demand for efficient and relevant solutions to various challenges faced by medical professionals have been increasing more than ever.

First, on the demand side, the market continues to expand against the backdrop of the increase in the elderly population. In particular, the number of atrial fibrillation cases in the cardiovascular field has continued to increase at a strong pace since the mid-2010s. Further, with the number of people aged 75 and older increasing significantly in the years ahead, the shift from surgeries to less physically taxing endovascular therapy (minimally invasive treatment) is also expected to gather pace. As minimally invasive treatment will gradually lower the age of eligible patients, it will lead to expansion of the medical device market, and provide a tailwind for the industry. We expect such structural expansion in demand to form a base that supports market growth in the future.

Secondly, chronic shortage of resources at medical institutions, which are on the supply side of medical care, has become a serious issue. Given the shortened working hours and staff shortage following workstyle reform of doctors, there is strong demand for medical devices that support streamlining of medical care including simplification of procedures and shortening of treatment time in a clinical environment. This is not just about the pursuit of therapeutic effects but signals that we are now moving into an era where products that succeed will be the ones contributing toward sustaining the medical care delivery system.

Thirdly, in terms of macroeconomy, the weakening of the yen and the worldwide inflation could also have an impact on our profit structure. Even as manufacturing expenses including raw material costs, logistics costs, and labor costs as well as selling, general and administrative expenses are increasing, it is difficult for us to pass on the rise in such costs immediately to the selling prices as the official prices of medical devices are set by the government under Japan's universal healthcare system. For that reason, we need to continuously monitor inflation as a risk that could put pressure on our profits.

In light of the above recognition of the environment, our important management challenges include diversifying domestic risk by expanding the business globally and implementing appropriate growth strategies to address the changes in the medical care trends. As for globalization, our urgent tasks are optimizing domestic products for the overseas market and establishing global quality standards. In terms of addressing the changes in the medical care trends, R&D related to pulsed field ablation (PFA) for arrhythmia treatment and the acquisition of pipeline assets such as stent graft and transcatheter aortic valve implantation (TAVI) for endovascular therapy are examples of our efforts to capture the opportunity. We aim to achieve both sustainable growth and profitability in this rapidly changing business environment through early incorporation of market needs into our product lineup, leveraging the unique hybrid business model combining our dual roles of manufacturer and distributor.

Status of business

For the six months ended September 30, 2026, we saw varied year-over-year performance across key financial metrics. Net sales grew by 7.1% and gross profit rose by 2.6%. Operating profit declined by 17.4%, while net income attributable to owners of the parent decreased by 7.2%. In the fourth year of the medium-term management plan (a five-year period from the fiscal year ended March 31, 2024 to the fiscal year ending March 31, 2028), we continued to work on the following five key initiatives of "Continuous Introduction of Competitive Products," "Expansion into New Therapeutic Areas," "Expansion of Global Sales," "Promotion of the OEM Business," and "Strengthening Management with a Focus on Capital Efficiency." Meanwhile, as part of our investments for future growth, we accelerated R&D activities related to the development of new products and the global optimization of our proprietary products, resulting in higher selling, general and administrative expenses. As a result, for the six months ended September 30, 2026, net sales increased while operating profit declined.

In terms of sales, both our existing business areas (EP/Ablation and Cardiovascular) and new business areas (Neurovascular and Gastrointestinal) grew. Despite the revision to reimbursement prices implemented in June 2026, net sales reached a record high for a six-month period. Net sales from EP/Ablation and Cardiovascular, which are positioned as core businesses within our existing business areas, increased by 10.3% and 4.1% year on year, respectively. Our new business areas also saw sales increase by 42.9% in Neurovascular and 34.4%* in Gastrointestinal, sustaining double-digit growth. Cardiac Rhythm Management, positioned as a stable business, posted a 7.0% decrease in sales.

Selling, general and administrative (SG&A) expenses increased by 1,613 million yen year-over-year, primarily due to R&D activities and higher personnel expenses, as well as increased outsourcing and other expenses related to a corporate acquisition. The increase also reflected the non-recurrence of a reversal of allowance for doubtful accounts that had been recognized in the same period of the previous fiscal year and recorded as a reduction in SG&A expenses. This resulted in a year-over-year decrease of 1,151 million yen in operating profit, with the operating margin of 17.4%.

Volatility in foreign currency exchange rates had a minimal short-term impact on procurement as our purchases of products from third parties made in yen accounted for approximately 70% of all transactions and we use the moving average method for cost of sales. However, the depreciation of the yen against the ringgit increased the cost ratio at our production site in Malaysia due to the translation of manufacturing expenses denominated in local currency.

Furthermore, we have mitigated supply risks associated with the deteriorating situation in the Middle East by securing raw materials in advance. As a result, there has been no material impact on product supply to date.

* Sales of Gastrointestinal included those from the terminated coronary intervention business; without this business, sales would have increased 41.6% year-over-year.

Business Performance

The earnings for the six months ended September 30, 2026 were as follows:

(Millions of yen, unless otherwise noted)

Product Category	Six months ended September 30, 2025		Six months ended September 30, 2026		YoY increase/ (decrease)	YoY % increase/ (decrease)
	Amount	% of net sales	Amount	% of net sales		
(i) Net sales	29,285	100.0	31,353	100.0	2,068	7.1
(ii) Gross profit	17,557	60.0	18,018	57.5	461	2.6
(iii) Operating profit	6,620	22.6	5,468	17.4	(1,151)	(17.4)
(iv) Ordinary profit	6,624	22.6	6,040	19.3	(584)	(8.8)
(v) Net income attributable to owners of the parent	4,774	16.3	4,430	14.1	(344)	(7.2)

(i) Net sales

Net sales were 31,353 million yen, an increase of 7.1% year-over-year. For more details, please refer to the "Sales by product" section later in this report.

(ii) Gross profit

Gross profit was 18,018 million yen, up 2.6% year-over-year. Lower selling prices due to new product promotions, revisions to reimbursement prices, and other factors, as well as higher manufacturing costs driven in part by soaring raw material costs, had an impact. However, increased sales volume more than compensated for this impact, resulting in higher gross profit.

The gross margin was 57.5%, a decrease of 250 bps year-over-year, due to the impact of selling prices noted above. Meanwhile, the proprietary product sales ratio increased by 210 bps year-over-year to 57.2%, reflecting increased sales of radiofrequency transseptal wires, intracardiac defibrillation catheter, and other products.

(iii) Operating profit

We reported operating profit of 5,468 million yen, a decrease of 17.4% year-over-year, and operating margin of 17.4% (a decrease of 520 bps year-over-year). Selling, general and administrative expenses were 12,550 million yen, an increase of 14.8% year-over-year. The main reasons for the increase are as follows:

- An increase in research and development expenses related to the development of PFA systems and other projects
- Higher personnel expenses from salary increases
- An increase in outsourcing expenses related to a corporate acquisition
- The absence of a reversal of allowance for doubtful accounts that had been recognized in the same period of the previous fiscal year and recorded as a reduction in SG&A expenses

(iv) Ordinary profit

Ordinary profit was 6,040 million yen, down 8.8% year-over-year. Non-operating income totaled 681 million yen, including gain on valuation of investment securities and reversal of allowance for doubtful accounts. In addition, non-operating expenses of 109 million yen were recognized, mainly consisting of foreign exchange losses.

(v) Net income attributable to owners of the parent

Net income attributable to owners of the parent was 4,430 million yen, marking a 7.2% decrease year-over-year. Extraordinary income included a gain on sale of investment securities of 346 million yen.

The income tax burden was 30.1%, up 260 bps.

Sales by product

(Millions of yen, unless otherwise noted)

Product Category	Six months ended September 30, 2025	Six months ended September 30, 2026	YoY increase/ (decrease)	YoY % increase/ (decrease)
Cardiac Rhythm Management	6,666	6,198	(467)	(7.0)
EP/Ablation	14,707	16,222	1,515	10.3
Cardiovascular	5,936	6,177	240	4.1
Neurovascular	1,187	1,696	509	42.9
Gastrointestinal	787	1,057	270	34.4
Total	29,285	31,353	2,068	7.1

*Note: The main products classified in each product category are as follows.

Cardiac Rhythm Management	Pacemaker, T-ICD (Transvenous Implantable Cardioverter Defibrillator), S-ICD (Subcutaneous Implantable Cardioverter Defibrillator), CRT-P (Cardiac Resynchronization Therapy Pacemaker), CRT-D (Cardiac Resynchronization Therapy Defibrillator), AED (Automated External Defibrillator), lead management device
EP/Ablation	Electrophysiology catheter, ablation catheter, intracardiac defibrillation catheter, esophageal temperature monitoring catheter, steerable sheath, hemostatic device for femoral vein, radiofrequency transseptal wire
Cardiovascular	Vascular graft, Frozen Elephant Trunk, stent graft, atrial septum defect closure device
Neurovascular	Embolic coil, aspiration catheter, microcatheter, stent retriever
Gastrointestinal	Bile-duct tube stent, biliary dilation balloon, contrast catheter, double-lumen dilator, ERCP guide wire, colonic stent, gastro duodenal stent, Radiofrequency ablation system for oncology

(i) Cardiac Rhythm Management

Net sales in Cardiac Rhythm Management reached 6,198 million yen, a decrease of 7.0% year-over-year. Pacemaker sales were sluggish as competitors' leadless pacemakers achieved greater market penetration. Net sales of the core product S-ICD have softened since the second quarter in the current fiscal year as competitors' newly launched products gained traction in new implant cases.

(ii) EP/Ablation

Net sales in EP/Ablation reached 16,222 million yen, an increase of 10.3% year-over-year. Sales of core product groups spearheaded overall sales growth, driven by an approximately 10% year-over-year rise in atrial fibrillation ablation procedures. By product category, intracardiac defibrillation catheters recorded growth, while net sales of hemostatic devices for femoral vein also remained strong thanks to an increase in the number of facilities adopting the product as well as an expanded product lineup. Further, radiofrequency transseptal wires, a proprietary product launched in March 2026, gained market share at a faster-than-expected pace.

(iii) Cardiovascular

Net sales in Cardiovascular reached 6,177 million yen, an increase of 4.1% year-over-year. The core product Frozen Elephant Trunk maintained its high market share in a stable market. Sales of abdominal stent graft also grew as enhanced sales measures proved effective.

(iv) Neurovascular

Net sales in Neurovascular reached 1,696 million yen, an increase of 42.9% year-over-year. Embolic coil sales remained strong, supported by solid demand for existing models, as well as the launch of new vascular embolization models beginning in the second quarter of the current fiscal year. Aspiration catheters continued to record double-digit growth, driven by a significant increase in sales volume, despite an approximately 10% decline in selling prices following the revision to reimbursement prices. Stent retrievers contributed to revenue increase as sales of the upgraded model expanded largely in line with the plan.

(v) Gastrointestinal

Net sales in Gastrointestinal amounted to 1,057 million yen, an increase of 34.4% year-over-year. Excluding the coronary intervention business, which was terminated in the fiscal year ended March 31, 2024, adjusted net sales increased 41.6%. The mainstay bile-duct tube stent generated significant revenue growth as sales, led by the new model, progressed ahead of plan, while supply shortages of competitors' products also contributed. Other products such as biliary dilation balloons and ERCP guide wires also performed well overall.

(2) Financial position

Analysis of the interim consolidated balance sheets

(i) Assets

The balance of current assets as of September 30, 2026 was 49,802 million yen, an increase of 755 million yen from the end of the previous fiscal year. This was mainly due to increases of 1,113 million yen in notes and accounts receivable - trade and 457 million yen in inventories, partially offset by a decrease of 783 million yen in cash and deposits, resulting from payments for dividends and income taxes.

The balance of fixed assets was 30,203 million yen, a decrease of 961 million yen from the end of the previous fiscal year. This was mainly due to decreases of 1,157 million yen in long-term loans receivable, 618 million yen in investment securities, and 657 million yen in accrued interest in "Other" under investments and other assets, partially offset by an increase of 1,701 million yen in buildings and structures.

As a result, the balance of total assets was 80,005 million yen, a decrease of 205 million yen from the end of the previous fiscal year.

(ii) Liabilities

The balance of current liabilities as of September 30, 2026 was 12,829 million yen, a decrease of 768 million yen from the end of the previous fiscal year. This was primarily due to decreases of 405 million yen in notes and accounts payable - trade and 243 million yen in accrued expenses included in "Other."

The balance of long-term liabilities was 762 million yen, an increase of 45 million yen from the end of the previous fiscal year. This was mainly due to an increase of 74 million yen in asset retirement obligations included in "Other," partially offset by a decrease of 28 million yen in lease liabilities included in "Other."

As a result, the balance of total liabilities was 13,591 million yen, a decrease of 722 million yen from the end of the previous fiscal year.

(iii) Net assets

The balance of net assets as of September 30, 2026 was 66,414 million yen, an increase of 516 million yen from the end of the previous fiscal year. This was mainly due to the recording of net income attributable to owners of the parent of 4,430 million yen, partially offset by dividend payments of 3,792 million yen.

Analysis of the interim consolidated statements of cash flows

The balance of cash and cash equivalents as of September 30, 2026 amounted to 11,711 million yen, a decrease of 782 million yen from the end of the previous fiscal year. Cash flows for the first six months of the fiscal year ending March 31, 2027 by activities were as follows.

(i) Cash flows from operating activities

Net cash provided by operating activities was 3,274 million yen (for the first six months of the previous fiscal year, net cash provided by operating activities was 3,495 million yen). The main factors are profit before income taxes of 6,338 million yen, despite an increase in trade notes and accounts receivable of 1,111 million yen, an increase in inventories of 456 million yen, and income taxes paid of 1,676 million yen, which decreased cash flows.

(ii) Cash flows from investing activities

Net cash used in investing activities was 242 million yen (for the first six months of the previous fiscal year, net cash used in investing activities was 1,023 million yen). The main factors are purchase of property, plant and equipment of 1,922 million yen, despite proceeds from collection of long-term loans receivable of 1,603 million yen.

(iii) Cash flows from financing activities

Net cash used in financing activities was 3,826 million yen (for the first six months of the previous fiscal year, net cash used in financing activities was 3,880 million yen), mainly due to dividends paid of 3,787 million yen.

(3) Consolidated financial guidance

The Company reaffirms its full-year consolidated earnings forecast for the fiscal year ending March 31, 2027, as announced on May 7, 2026.

For the six months ended September 30, 2026, in terms of net sales, EP/Ablation, Neurovascular, and Gastrointestinal performed strongly relative to the forecast, offsetting somewhat weaker net sales of Cardiac Rhythm Management. Overall, net sales progressed slightly ahead of our initial forecast. We anticipate that net sales will progress generally in line with our initial guidance in the third quarter and beyond.

In terms of profit, each profit figure significantly exceeded the plan for the first half, mainly due to delays in the incurrence of research and development expenses during the six months ended September 30, 2026. However, as these expenses are expected to be largely incurred during the current fiscal year from the third quarter onward, we expect full-year profit figures to remain generally in line with our initial guidance.

Should any revisions become necessary due to various factors, we will promptly disclose them.

2. Interim Consolidated Financial Statements and Major Notes

(1) Interim consolidated balance sheets

(Millions of yen)

	As of March 31, 2026	As of September 30, 2026
Assets		
Current assets		
Cash and deposits	12,494	11,711
Notes and accounts receivable - trade	14,550	15,663
Inventories	20,129	20,587
Other	1,871	1,839
Total current assets	49,046	49,802
Fixed assets		
Property, plant and equipment		
Buildings and structures, net	6,823	8,525
Other, net	7,087	6,755
Total property, plant and equipment	13,911	15,281
Intangible assets	1,564	1,535
Investments and other assets		
Investment securities	7,350	6,732
Long-term loans receivable	2,793	1,635
Retirement benefit asset	162	171
Other	6,938	6,200
Allowance for doubtful accounts	(1,557)	(1,354)
Total investments and other assets	15,688	13,386
Total fixed assets	31,164	30,203
Total assets	80,211	80,005
Liabilities		
Current liabilities		
Notes and accounts payable - trade	4,432	4,027
Short-term borrowings	2,900	2,900
Accounts payable - other	1,128	1,186
Income taxes payable	1,694	1,690
Provision for bonuses	1,870	1,814
Provision for bonuses for directors	30	20
Other	1,541	1,190
Total current liabilities	13,597	12,829
Long-term liabilities		
Provision for director’s stock based compensation	85	85
Other	630	676
Total long-term liabilities	716	762
Total liabilities	14,314	13,591
Net assets		
Shareholders’ equity		
Share capital	2,115	2,115
Capital surplus	4,418	4,492
Retained earnings	59,083	59,721
Treasury stock	(1,208)	(1,262)
Total shareholders’ equity	64,409	65,066
Accumulated other comprehensive income		
Net unrealized holding gains or losses on securities	58	(125)
Foreign currency translation adjustment	1,138	1,185
Remeasurements of defined benefit plans	243	205
Total accumulated other comprehensive income	1,441	1,265
Share acquisition rights	47	82
Total net assets	65,897	66,414
Total liabilities and net assets	80,211	80,005

(2) Interim consolidated statements of income and interim consolidated statements of comprehensive income

(Interim consolidated statements of income)

(Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Net sales	29,285	31,353
Cost of sales	11,727	13,334
Gross profit	17,557	18,018
Selling, general and administrative expenses	10,937	12,550
Operating profit	6,620	5,468
Non-operating income		
Interest income	59	34
Dividend income	28	24
Gain on valuation of investment securities	–	367
Reversal of allowance for doubtful accounts	–	203
Other	8	51
Total non-operating income	95	681
Non-operating expenses		
Interest expenses	18	18
Loss on valuation of investment securities	19	–
Foreign exchange losses	25	70
Provision of allowance for doubtful accounts	3	–
Commission expenses	7	8
Other	16	11
Total non-operating expenses	90	109
Ordinary profit	6,624	6,040
Extraordinary income		
Gain on sale of fixed assets	0	1
Gain on sale of investment securities	–	346
Total extraordinary income	0	347
Extraordinary losses		
Loss on retirement of fixed assets	42	48
Total extraordinary losses	42	48
Profit before income taxes	6,582	6,338
Income taxes - current	1,608	1,673
Income taxes - deferred	199	235
Total income taxes	1,807	1,908
Net income	4,774	4,430
Net income attributable to owners of the parent	4,774	4,430

(Interim consolidated statements of comprehensive income)

(Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Net income	4,774	4,430
Other comprehensive income		
Net unrealized holding gains or losses on securities	116	(184)
Foreign currency translation adjustment	(121)	46
Retirement benefits liability adjustment	(102)	(38)
Total other comprehensive income	(107)	(176)
Comprehensive income	4,667	4,254
Comprehensive income attributable to:		
Owners of the parent	4,667	4,254

(3) Interim consolidated statements of cash flows

(Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Cash flows from operating activities		
Profit before income taxes	6,582	6,338
Depreciation	814	811
Amortization of long-term prepaid expenses	159	153
Increase (decrease) in allowance for doubtful accounts	(208)	(203)
Increase (decrease) in provision for bonuses	(208)	(55)
Increase (decrease) in provision for bonuses for directors	(58)	(10)
Increase (decrease) in retirement benefit liability	(112)	(64)
Increase (decrease) in provision for directors' stock based compensation	(85)	(0)
Interest and dividend income	(87)	(59)
Interest expenses	18	18
Loss (gain) on sale and retirement of fixed assets	42	47
Loss (gain) on valuation of investment securities	19	(367)
Loss (gain) on sale of investment securities	–	(346)
Decrease (increase) in trade notes and accounts receivables	(606)	(1,111)
Decrease (increase) in inventories	(1,187)	(456)
Decrease (increase) in accounts receivable - other	(63)	235
Increase (decrease) in trade notes and accounts payables	97	(405)
Increase (decrease) in accrued consumption taxes	(104)	(118)
Increase (decrease) in accrued expenses	(180)	(243)
Other, net	188	113
Subtotal	5,019	4,277
Interest and dividends received	37	692
Interest paid	(18)	(18)
Income taxes paid	(1,543)	(1,676)
Net cash provided by (used in) operating activities	3,495	3,274
Cash flows from investing activities		
Purchase of property, plant and equipment	(672)	(1,922)
Purchase of intangible assets	(26)	(181)
Proceeds from sale of fixed assets	0	1
Purchase of investment securities	(40)	(88)
Proceeds from sale of investment securities	–	786
Proceeds from distributions from investment partnerships	–	385
Short-term loan advances	–	(16)
Long-term loan advances	(3)	(464)
Proceeds from collection of long-term loans receivable	5	1,603
Other payments	(407)	(350)
Other proceeds	119	4
Net cash provided by (used in) investing activities	(1,023)	(242)
Cash flows from financing activities		
Repayments of long-term borrowings	(60)	–
Repayments of lease liabilities	(101)	(38)
Dividends paid	(3,718)	(3,787)
Net cash provided by (used in) financing activities	(3,880)	(3,826)
Effect of exchange rate change on cash and cash equivalents	24	11
Net increase (decrease) in cash and cash equivalents	(1,384)	(782)
Cash and cash equivalents at beginning of period	11,014	12,494
Cash and cash equivalents at end of period	*1 9,630	*1 11,711

(4) Notes to interim consolidated financial statements

Going concern assumption

None

Significant changes in shareholders' equity

None

Changes in scope of consolidation or application of equity method

JLL Med USA Inc. was newly established and has therefore been included in the scope of consolidation from the six months ended September 30, 2026.

Interim consolidated statements of cash flows

*1 The relationship between the balance of cash and cash equivalents at the end of the periods and the amount of items listed in the interim consolidated balance sheets is as follows:

(Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Cash and deposits	9,630	11,711
Cash and cash equivalents	9,630	11,711

Segment information, etc.

[Segment information]

Six months ended September 30, 2025 (from April 1, 2025 to September 30, 2025)

The Company and its consolidated subsidiaries are engaged in the manufacture and sale of medical devices, with principal customers located in Japan. There are no reportable segments among the components of the Company and its consolidated subsidiaries for which discrete financial information is available and whose operating results are regularly reviewed by the Board of Directors to make decisions about management resources to be allocated and assess business performance.

Six months ended September 30, 2026 (from April 1, 2026 to September 30, 2026)

The Company and its consolidated subsidiaries are engaged in the manufacture and sale of medical devices, with principal customers located in Japan. There are no reportable segments among the components of the Company and its consolidated subsidiaries for which discrete financial information is available and whose operating results are regularly reviewed by the Board of Directors to make decisions about management resources to be allocated and assess business performance.

Significant subsequent events

At the meeting of its Board of Directors held on September 29, 2026, the Company resolved to acquire U.S.-based Cross Vascular, Inc. ("Cross Vascular") through JLL Med USA Inc., a wholly owned subsidiary of the Company, and make Cross Vascular an indirect wholly owned subsidiary of the Company. On October 1, 2026, the Company acquired the shares of Cross Vascular, making it an indirect wholly owned subsidiary.

For details, please refer to "Japan Lifeline Announces Acquisition of U.S.-Based Cross Vascular and Change in Specified Subsidiary Following Capital Increase" announced on September 29, 2026.

3. Other

Status of production, orders received and sales

(i) Production

The production results for the six months ended September 30, 2025 and 2026, by product category, were as follows. There were no significant changes.

(Millions of yen)

Product Category	Six months ended September 30, 2025	Six months ended September 30, 2026	YoY % increase/ (decrease)
Cardiac Rhythm Management	5	7	39.2
EP/Ablation	3,132	3,725	18.9
Cardiovascular	836	846	1.3
Gastrointestinal	384	378	(1.4)
Total	4,358	4,958	13.8

Notes: 1. Figures are based on manufacturing cost.

2. Neurovascular has been omitted because there was no production during either the six months ended September 30, 2025, or the six months ended September 30, 2026.

(ii) Orders received

As the Group's business model generally does not generate order backlogs, this information is omitted.

(iii) Sales results

Please refer to "1. Overview of Financial Performance (1) Operating results" on page 2 of the attached materials.